Skip to main content
. Author manuscript; available in PMC: 2017 Dec 15.
Published in final edited form as: J Immunol. 2016 Nov 9;197(12):4603–4612. doi: 10.4049/jimmunol.1601197

Figure 1. Antibody functional activity across subject groups and control samples.

Figure 1

The functional activity of purified antibodies from HIV infected treated (Tx), untreated (Untx), or elite controllers (EC), Vax004 vaccinees (VAX004), and VAX004 placebo recipients (Placebo) was assessed across a suite of cell-based assays of antibody effector function including ADCC activity (BVADCC, GTL ADCC, RFADCC, LUC ADCC), ADCVI, and phagocytic activity (Virion Phagocytosis, ADCP). Replicates of polyclonal IVIG, HIVIG, and HIVIG-C were used as negative and positive controls and to assess assay reproducibility, and were evaluated at a different concentration (gray shaded region). AUC denotes area under the titration curve. Activity magnitudes (y-axis scales) are described in the materials and methods and should not be compared across assays.